Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Other Non-Current Assets (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Other Non-Current Assets for 8 consecutive years, with $13.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Assets rose 37.95% year-over-year to $13.7 million, compared with a TTM value of $13.7 million through Sep 2025, up 37.95%, and an annual FY2024 reading of $11.1 million, up 91.19% over the prior year.
  • Other Non-Current Assets was $13.7 million for Q3 2025 at Bicycle Therapeutics, down from $13.8 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $13.8 million in Q2 2025 and bottomed at $2.2 million in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $7.5 million, with a median of $6.4 million recorded in 2024.
  • The sharpest move saw Other Non-Current Assets surged 151.69% in 2023, then tumbled 45.83% in 2024.
  • Year by year, Other Non-Current Assets stood at $3.4 million in 2021, then soared by 145.3% to $8.5 million in 2022, then plummeted by 31.52% to $5.8 million in 2023, then soared by 91.19% to $11.1 million in 2024, then rose by 23.82% to $13.7 million in 2025.
  • Business Quant data shows Other Non-Current Assets for BCYC at $13.7 million in Q3 2025, $13.8 million in Q2 2025, and $12.4 million in Q1 2025.